Rafael Holdings, INC. (RFL) — SEC Filings

Overview

Rafael Holdings, INC. (RFL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 22, 2026: On April 22, 2026, Rafael Holdings, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing includes a press release dated April 22, 2026, and associated financial exhibits in XBRL format. The company's mailing and business address is 520 Broad Street, Newark, NJ 0

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 2 bearish, 35 neutral, 2 mixed. The dominant filing sentiment for Rafael Holdings, INC. is neutral.

Filing Type Overview

Rafael Holdings, INC. (RFL) has filed 21 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 8-K/A, 2 10-K/A, 2 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (39)

• Rafael Holdings Files 8-K with Press Release — 8-K · Apr 22, 2026 Risk: low
  On April 22, 2026, Rafael Holdings, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing includes a press release dated Ap
• Rafael Holdings' Loss Widens on Soaring R&D for Key Drug Candidate — 10-Q · Dec 12, 2025 Risk: high
  Rafael Holdings, Inc. (RFL) reported a consolidated net loss of $9.797 million for the three months ended October 31, 2025, an increase from the $9.211 million
• Rafael Holdings Files 8-K on Financials — 8-K · Dec 11, 2025 Risk: low
  On December 11, 2025, Rafael Holdings, Inc. filed an 8-K report detailing its financial results and operations. The filing includes information on its Class B C
• 8-K Filing — 8-K · Dec 2, 2025
• Rafael Holdings Seeks Shareholder Nod for Director Slate, Equity Plan Boost — DEF 14A · Nov 18, 2025 Risk: medium
  Rafael Holdings, Inc. (RFL) is holding its Annual Meeting on January 8, 2026, to elect six directors, ratify CohnReznick LLP as its independent auditor for Fisc
• Rafael Holdings Bets Big on Rare Disease Drug Amid Portfolio Shifts — 10-K · Oct 29, 2025 Risk: high
  Rafael Holdings, Inc. (RFL) is a biotechnology company primarily focused on developing Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1), a rare genetic di
• Rafael Holdings Files 8-K on Officer/Director Changes — 8-K · Oct 28, 2025 Risk: medium
  Rafael Holdings, Inc. filed an 8-K on October 28, 2025, reporting events as of October 23, 2025. The filing pertains to the departure of directors or certain of
• Rafael Holdings Files 8-K Report — 8-K · Oct 10, 2025 Risk: low
  On October 10, 2025, Rafael Holdings, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the filing of financial statements a
• Rafael Holdings CFO Departs, New CFO Appointed — 8-K · Aug 7, 2025 Risk: medium
  On August 4, 2025, Rafael Holdings, Inc. filed an 8-K report detailing the departure of its Chief Financial Officer, Dr. David J. Gury, effective August 1, 2025
• Rafael Holdings Files 8-K: Director/Officer Changes & Bylaw Amendments — 8-K · Jul 18, 2025 Risk: medium
  Rafael Holdings, Inc. filed an 8-K on July 18, 2025, reporting events as of July 14, 2025. The filing covers the departure of directors, election of new directo
• Rafael Holdings Files 8-K Report — 8-K · Jun 18, 2025 Risk: low
  On June 18, 2025, Rafael Holdings, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 520 Broad Street, New
• Rafael Holdings Narrows Q3 Loss to $1.5M Amidst Zero Revenue — 10-Q · Jun 11, 2025 Risk: high
  Rafael Holdings, Inc. reported no revenue for the three and nine months ended April 30, 2025, consistent with its prior-year periods, as it continues to operate
• Rafael Holdings Files 8-K on Equity Sales — 8-K · Jun 4, 2025 Risk: medium
  On June 4, 2025, Rafael Holdings, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also included other events and financia
• Rafael Holdings Files 8-K/A Amendment — 8-K/A · May 20, 2025 Risk: medium
  Rafael Holdings, Inc. filed an amendment (8-K/A) on May 20, 2025, to its Form 8-K originally filed on April 29, 2025. This amendment pertains to "Other Events"
• Rafael Holdings Files 8-K: Material Agreement & Equity Sales — 8-K · May 6, 2025 Risk: medium
  On May 6, 2025, Rafael Holdings, Inc. filed an 8-K report detailing a material definitive agreement, unregistered sales of equity securities, and financial stat
• Rafael Holdings Files 8-K Amendment — 8-K/A · May 5, 2025 Risk: low
  Rafael Holdings, Inc. filed an amendment (8-K/A) on May 5, 2025, to its Form 8-K, originally filed on April 29, 2025. This amendment pertains to the financial s
• Rafael Holdings Files 8-K Report — 8-K · Apr 29, 2025 Risk: low
  On April 29, 2025, Rafael Holdings, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements and exhibits. No specific fina
• Rafael Holdings Files 8-K/A Amendment — 8-K/A · Apr 28, 2025 Risk: low
  Rafael Holdings, Inc. filed an amendment (8-K/A) on April 28, 2025, to a previous report concerning events on March 25, 2025. The filing primarily relates to fi
• Rafael Holdings Reports Board and Executive Compensation Changes — 8-K · Apr 24, 2025 Risk: medium
  On April 23, 2025, Rafael Holdings, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the ele
• Rafael Holdings CFO Departs; Interim CFO Appointed — 8-K · Mar 26, 2025 Risk: medium
  On March 25, 2025, Rafael Holdings, Inc. announced the departure of its Chief Financial Officer, David J. Glick, effective March 24, 2025. The company also anno
• Rafael Holdings Reports Shareholder Vote — 8-K · Mar 25, 2025 Risk: medium
  Rafael Holdings, Inc. filed an 8-K on March 25, 2025, reporting that a matter was submitted to a vote of its security holders on March 20, 2025. The filing does
• Rafael Holdings Files Q1 2025 10-Q — 10-Q · Mar 14, 2025 Risk: low
  Rafael Holdings, Inc. filed its quarterly report for the period ending January 31, 2025. The company, incorporated in Delaware and headquartered in Newark, New
• Rafael Holdings Enters Material Definitive Agreement — 8-K · Feb 10, 2025 Risk: medium
  On February 4, 2025, Rafael Holdings, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offi
• Rafael Holdings Reports on Shareholder Vote Matters — 8-K · Jan 13, 2025 Risk: low
  Rafael Holdings, Inc. filed an 8-K on January 13, 2025, reporting on a submission of matters to a vote of security holders that occurred on January 9, 2025. The
• Rafael Holdings Files 10-K/A Amendment — 10-K/A · Jan 8, 2025 Risk: low
  Rafael Holdings, Inc. filed an amendment (Amendment No. 2) to its annual report on Form 10-K for the fiscal year ended July 31, 2024. This filing, dated January
• Rafael Holdings Files 8-K Report — 8-K · Dec 23, 2024 Risk: low
  On December 23, 2024, Rafael Holdings, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No specifi
• Rafael Holdings Files 10-K Amendment — 10-K/A · Dec 20, 2024 Risk: low
  Rafael Holdings, Inc. filed an amendment (Amendment No. 1) to its annual report on Form 10-K for the fiscal year ended July 31, 2024. The filing, dated December
• Rafael Holdings Files Q3 2024 10-Q — 10-Q · Dec 11, 2024 Risk: low
  Rafael Holdings, Inc. filed its quarterly report on Form 10-Q for the period ended October 31, 2024. The company, incorporated in Delaware, is involved in the P
• Rafael Holdings Files 2025 Proxy Statement — DEF 14A · Nov 19, 2024 Risk: low
  Rafael Holdings, Inc. filed its definitive proxy statement on November 19, 2024, for its 2025 annual meeting of stockholders, scheduled for January 9, 2025. The
• Rafael Holdings Files 2024 Annual Report — 10-K · Nov 7, 2024 Risk: low
  Rafael Holdings, Inc. filed its annual report on Form 10-K for the fiscal year ended July 31, 2024. The company, incorporated in Delaware and headquartered in N
• Jonas Amends Rafael Holdings Stake Filing — SC 13D/A · Sep 30, 2024 Risk: medium
  Howard S. Jonas has filed an amendment (No. 4) to Schedule 13D for Rafael Holdings, Inc., indicating a change in beneficial ownership as of September 25, 2024.
• Rafael Holdings Enters Material Definitive Agreement — 8-K · Aug 22, 2024 Risk: medium
  On August 21, 2024, Rafael Holdings, Inc. entered into a material definitive agreement related to a direct financial obligation. The company, incorporated in De
• Rafael Holdings Appoints New CEO, CFO, and Directors — 8-K · Aug 8, 2024 Risk: medium
  Rafael Holdings, Inc. announced on August 5, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new direc
• Jonas Amends Rafael Holdings Stake — SC 13D/A · Jun 18, 2024 Risk: medium
  Howard Jonas has amended his Schedule 13D filing for Rafael Holdings, Inc. on June 13, 2024. This amendment, the third to the filing, indicates a change in the
• Rafael Holdings Files Q1 2024 10-Q — 10-Q · Jun 14, 2024 Risk: low
  Rafael Holdings, Inc. filed its 10-Q for the quarterly period ended April 30, 2024. The company, incorporated in Delaware, is primarily involved in real estate.
• Rafael Holdings Files Amendment to 8-K — 8-K/A · May 23, 2024 Risk: low
  Rafael Holdings, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on May 23, 2024, related to financial statements and exhibits. The original report da
• Rafael Holdings, Inc. Files 10-Q for Period Ended January 31, 2024 — 10-Q · Mar 14, 2024 Risk: low
  Rafael Holdings, Inc. (RFL) filed a Quarterly Report (10-Q) with the SEC on March 14, 2024. Rafael Holdings, Inc. filed a 10-Q quarterly report for the period e
• Rafael Holdings Completes Asset Acquisition/Disposition — 8-K · Mar 13, 2024 Risk: medium
  On March 13, 2024, Rafael Holdings, Inc. filed an 8-K report indicating the completion of an acquisition or disposition of assets. The filing details financial
• Rafael Holdings Files 8-K on Shareholder Vote Matters — 8-K · Jan 16, 2024
  Rafael Holdings, Inc. filed an 8-K on January 16, 2024, reporting an event that occurred on January 10, 2024, related to the submission of matters to a vote of

Risk Profile

Risk Assessment: Of RFL's 37 recent filings, 3 were flagged as high-risk, 16 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Rafael Holdings, INC.'s most recent 10-Q filing (Dec 12, 2025):

• Revenue: $240K
• Net Income: -$9.797M
• EPS: -$0.19
• Debt-to-Equity: 0.18
• Cash Position: $45.539M
• Operating Margin: -3002.9%
• Total Assets: $105.375M
• Total Debt: $16.195M

Key Executives

• Howard S. Jonas
• Joyce Mason
• Alan M. Grayson
• Markus W. Sieger
• Mark N. Stein
• Michael J. Weiss
• N. Scott Fine
• Susan Bernstein
• Dr. David J. Gury
• Mr. Jonathan S. Gury
• David J. Glick
• Michael J. Loner
• David J. Feldman
• David M. Miller
• Howard Jonas

Industry Context

The biotechnology sector, particularly in rare diseases, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like Rafael Holdings focus on specific unmet medical needs, such as Niemann-Pick Disease Type C1, where successful drug development can lead to substantial market opportunities but also faces intense competition and scientific risk. The industry trend involves strategic mergers and acquisitions to consolidate pipelines and leverage expertise.

Top Tags

amendment (7) · 8-K (4) · filing (4) · corporate-governance (4) · sec-filing (4) · 8-k (4) · 10-Q (4) · pharmaceuticals (4) · shareholder-vote (3) · disclosure (2)

Key Numbers

• CIK Number: 0001713863 — Unique identifier for Rafael Holdings, Inc. in SEC filings.
• Filing Date: 2026-04-22 — Date the 8-K report was accepted by the SEC.
• Consolidated Net Loss: $9.797M — Increased from $9.211 million in the prior year, reflecting higher expenses.
• Total Revenue: $240K — Increased from $128 thousand in the prior year, driven by new product revenue.
• Research and Development Expenses: $7.484M — Significantly increased from $1.326 million in the prior year, due to focus on Trappsol Cyclo.
• Cash and Cash Equivalents: $45.539M — Decreased from $52.769 million on July 31, 2025, indicating cash burn.
• Loss per share (Basic and Diluted): $0.19 — Decreased from $0.37 in the prior year, despite higher net loss, due to increased share count.
• Weighted average shares outstanding: 51,184,407 — Increased from 24,062,854 in the prior year, impacting EPS calculation.
• Net cash used in operating activities: $6.806M — Increased from $3.042 million in the prior year, reflecting higher operational costs.
• Ownership of Cyclo Therapeutics, LLC: 100% — Achieved through the merger on March 25, 2025.
• Ownership of LipoMedix Pharmaceuticals Ltd.: 95% — Majority equity interest as of October 31, 2025.
• Ownership of Rafael Medical Devices, LLC: 73% — Equity interest as of October 31, 2025.
• Shares of Class B Common Stock: 1,000,000 — Proposed increase for the 2021 Equity Incentive Plan
• Total shares issued and outstanding: 51,762,801 — As of November 11, 2025 Record Date
• Shares of Class A Common Stock: 787,163 — Outstanding as of November 11, 2025

Related Companies

RFL-W · RHDG

Frequently Asked Questions